Match!
  • References (39)
  • Citations (2)
Cite
References39
Newest
Published on Sep 1, 2018in Brain Pathology6.16
Claire Paquet23
Estimated H-index: 23
(French Institute of Health and Medical Research),
James A. R. Nicoll57
Estimated H-index: 57
(University of Southampton)
+ 4 AuthorsDelphine Boche24
Estimated H-index: 24
(University of Southampton)
Aβ immunisation of Alzheimer's disease (AD) patients in the AN1792 (Elan Pharmaceuticals) trial caused Aβ removal and a decreased density of neurons in the cerebral cortex. As preservation of neurons may be a critical determinant of outcome after Aβ immunisation, we have assessed the impact of previous Aβ immunisation on the expression of a range of apoptotic proteins in post-mortem human brain tissue. Cortex from 13 AD patients immunised with AN1792 (iAD) and from 27 non-immunised AD (cAD) case...
Published on Jan 1, 2018in Journal of Cerebral Blood Flow and Metabolism6.04
J. Scott Miners16
Estimated H-index: 16
(UoB: University of Bristol),
Isabel Schulz1
Estimated H-index: 1
(UoB: University of Bristol),
Seth Love54
Estimated H-index: 54
(UoB: University of Bristol)
Recent studies implicate loss of pericytes in hypoperfusion and blood–brain barrier (BBB) leakage in Alzheimer's disease (AD). In this study, we have measured levels of the pericyte marker, platelet-derived growth factor receptor-β (PDGFRB), and fibrinogen (to assess blood–brain barrier leakage), and analyzed their relationship to indicators of microvessel density (von Willebrand factor level), ante-mortem oxygenation (myelin-associated glycoprotein:proteolipid protein-1 ratio and vascular endot...
Published on Dec 1, 2016in Journal of Neuroinflammation5.70
Thais Minett18
Estimated H-index: 18
(University of Cambridge),
John Classey3
Estimated H-index: 3
(University of Southampton)
+ 7 AuthorsMrc Cfas9
Estimated H-index: 9
Background Genetic risk factors for Alzheimer’s disease imply that inflammation plays a causal role in development of the disease. Experimental studies suggest that microglia, as the brain macrophages, have diverse functions, with their main role in health being to survey the brain parenchyma through highly motile processes.
Published on Nov 1, 2016in Brain11.81
Olivia Skrobot7
Estimated H-index: 7
(UoB: University of Bristol),
Johannes Attems44
Estimated H-index: 44
(Newcastle University)
+ 10 AuthorsJames Neal40
Estimated H-index: 40
(Cardiff University)
There are no generally accepted protocols for post-mortem assessment in cases of suspected vascular cognitive impairment. Neuropathologists from seven UK centres have collaborated in the development of a set of vascular cognitive impairment neuropathology guidelines (VCING), representing a validated consensus approach to the post-mortem assessment and scoring of cerebrovascular disease in relation to vascular cognitive impairment. The development had three stages: (i) agreement on a sampling pro...
Published on Sep 1, 2016in Nature43.07
Jeff Sevigny4
Estimated H-index: 4
,
Ping Chiao5
Estimated H-index: 5
+ 25 AuthorsYan Ling3
Estimated H-index: 3
Aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ, reduces soluble and insoluble Aβ in the brain, an action accompanied by a dose-dependent slowing of clinical decline in treated patients.
Published on Jun 1, 2016in Embo Molecular Medicine10.62
Dennis J. Selkoe161
Estimated H-index: 161
(Brigham and Women's Hospital),
John Hardy149
Estimated H-index: 149
(UCL Institute of Neurology)
Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protei...
Published on Aug 25, 2015in Neurology8.69
Enchi Liu14
Estimated H-index: 14
,
Mark Schmidt20
Estimated H-index: 20
+ 20 AuthorsNick C. Fox112
Estimated H-index: 112
Objective: To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using 11 C-Pittsburgh compound B ( 11 C-PiB)-PET. Methods: Two phase 3 clinical trials, 1 each in apolipoprotein APOE e4 carriers and noncarriers, were conducted in patients with mild to moderate Alzheimer disease dementia. Bapineuzumab, an anti-Aβ monoclonal antibody, or placebo, was administered by IV infusion every 13 weeks for 78 weeks. PET substudies assessed change in brain fibrillar Aβ over 71 weeks using an...
Published on Jun 1, 2015in Neuropathology and Applied Neurobiology6.88
Jay Amin4
Estimated H-index: 4
(University of Southampton),
Claire Paquet23
Estimated H-index: 23
(French Institute of Health and Medical Research)
+ 6 AuthorsDelphine Boche24
Estimated H-index: 24
(University of Southampton)
Aims Active amyloid-β (Aβ) immunotherapy in Alzheimer's disease (AD) induces removal of Aβ and phosphorylated tau (ptau). Glycogen synthase kinase (GSK)-3β is a kinase, responsible for phosphorylation of tau, activation of which can be induced by phosphorylated double-stranded RNA-dependent protein kinase (pPKR). Using a post-mortem cohort of immunized AD cases, we investigated the effect of Aβ immunization on GSK-3β expression and pPKR. Methods We immunostained 11 immunized AD cases and 28 unim...
Published on Apr 1, 2015in The Journal of Pathology5.94
Claire Paquet23
Estimated H-index: 23
(French Institute of Health and Medical Research),
Jay Amin4
Estimated H-index: 4
(University of Southampton)
+ 8 AuthorsJacques Hugon28
Estimated H-index: 28
(French Institute of Health and Medical Research)
Amyloid-beta peptide (Abeta) immunization of Alzheimer's disease (AD) patients has been reported to induce amyloid plaque removal, but with little impact on cognitive decline. We have explored the consequences of Abeta immunotherapy on neurons in post mortem brain tissue. Eleven immunized (AN1792, Elan Pharmaceuticals) AD patients were compared to 28 non-immunized AD cases. Immunohistochemistry on sections of neocortex was performed for neuron-specific nuclear antigen (NeuN), neurofilament prote...
Published on Dec 1, 2014in Acta Neuropathologica18.17
Kenji Sakai12
Estimated H-index: 12
(University of Southampton),
Delphine Boche24
Estimated H-index: 24
(University of Southampton)
+ 4 AuthorsJames A. R. Nicoll57
Estimated H-index: 57
(University of Southampton)
Aβ immunotherapy for Alzheimer’s disease (AD) results in the removal of Aβ plaques and increased cerebral amyloid angiopathy (CAA). In current clinical trials, amyloid-related imaging abnormalities (ARIAs), putatively due to exacerbation of CAA, are concerning side effects. We aimed to assess the role of the Aβ transporter apolipoprotein E (apoE) in the exacerbation of CAA and development of CAA-associated vasculopathy after Aβ immunotherapy. 12 Aβ42-immunized AD (iAD; AN1792, Elan Pharmaceutica...
Cited By2
Newest
Published in CNS Drugs4.19
Luke McAlary5
Estimated H-index: 5
,
Steven S. Plotkin20
Estimated H-index: 20
,
Neil R. Cashman49
Estimated H-index: 49
Published on Jul 15, 2019in Nature Reviews Neurology21.16
Thomas Wisniewski69
Estimated H-index: 69
(NYU: New York University)
A new report presents post-mortem neuropathological follow-up of patients 4 months to 15 years after they received active amyloid-β (Aβ) immunization during its first trial in Alzheimer disease. The study documents effects on plaque clearance, tau pathology, plasma anti-Aβ antibody titres and final cognitive status; variability was seen between patients.
Published on Jul 1, 2019in Brain11.81
Cassia R. Overk14
Estimated H-index: 14
(UCSD: University of California, San Diego),
Eliezer Masliah139
Estimated H-index: 139
(NIH: National Institutes of Health)